Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bellicum Pharmaceuticals Inc (BLCM)

Bellicum Pharmaceuticals Inc (BLCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Bellicum Pharmaceuticals Inc 3730 Kirby Drive Suite 1200 Houston TX 77098 USA

www.bellicum.com P: 281-454-3424

Description:

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas.

Key Statistics

Overview:

Market Capitalization, $K 727
Enterprise Value, $K -3,073
Shares Outstanding, K 9,717
Annual Sales, $ 1,500 K
Annual Net Income, $ -24,970 K
Last Quarter Sales, $ 1,000 K
Last Quarter Net Income, $ -760 K
EBIT, $ -23,840 K
EBITDA, $ -23,830 K
60-Month Beta 1.39
% of Insider Shareholders 10.30%
% of Institutional Shareholders 4.93%
Float, K 8,716
% Float 89.70%
Short Volume Ratio 0.15

Growth:

1-Year Return -91.18%
3-Year Return -98.32%
5-Year Return -99.77%
5-Year Revenue Growth 689.47%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.02 on 11/14/23
Latest Earnings Date 03/05/24
Earnings Per Share ttm -0.52
EPS Growth vs. Prev Qtr 91.67%
EPS Growth vs. Prev Year 91.30%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 02/06/20

BLCM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -157.93%
Profit Margin % -1,664.67%
Debt/Equity 0.00
Price/Sales 12.72
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.48
Interest Coverage -3.37
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar